Gibson Dunn Advises BVF Partners L.P. on up to $24.5 Million Financing for Entera Bio

Firm News  |  April 2, 2026

---

Gibson Dunn represented BVF Partners L.P. in its up to $24.5 million private placement financing for Entera Bio Ltd., a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care.

Gibson Dunn regularly advises life sciences investors on private placement financings for clinical-stage biopharmaceutical companies.

The Gibson Dunn team included Ryan Murr, Branden Berns, and Jasmine Vitug.